

Rec'd PCT/PTO 28 NOV 2005

John Anderson

9194199354

IPTL

01:48:05 p.m.

11-28-2005

1 / 5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>In re United States Patent Application of:</b>		)	<b>Docket No.:</b>	<b>4240-130</b>
<b>Applicants:</b>	<b>KANG, Kyung Sun</b>	)	<b>Examiner:</b>	<b>Not Yet Assigned</b>
<b>Application No.:</b>	<b>10/555,852</b>	)	<b>Art Unit:</b>	<b>Not Yet Assigned</b>
<b>Filing Date:</b>	<b>November 9, 2005</b>	)	<b>Customer No.:</b>	
<b>Title:</b>	<b>MULTIPOTENT STEM CELLS ISOLATED FROM UMBILICAL CORD BLOOD AND THE CELLULAR THERAPEUTIC AGENT COMPRISING THE SAME FOR TREATING ISCHEMIC DISEASE</b>	)	<div style="border: 1px solid black; padding: 20px; text-align: center;"><b>23448</b></div>	
		)		
		)		
		)		
		)		

**FACSIMILE TRANSMISSION CERTIFICATE**

I hereby certify that I am filing this document in the US Patent and Trademark Office on November 28, 2005, addressed to Mail Stop: PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 and transmitted via facsimile to USPTO/PCT Central Fax Number (571) 273-3201 under the provisions of 37 CFR 1.8.



Steven J. Hultquist

November 28, 2005

Date

5

Number of Pages Transmitted

**SECOND PRELIMINARY AMENDMENT**

Mail Stop: PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Prior to examination of the above-identified new national phase patent application, please amend the application as set out in Section I (Amendments to the Claims) hereof. Remarks concerning the amendments to the specification and claims are set out in Section II (Remarks) hereof.